Winner 2015.

Methods	Randomized, placebo‐controlled, double‐blind cross‐over trial of oral sumatriptan + naproxen sodium
Participants	Male and female adolescents 12‐17 years of age meeting ICHD‐2 criteria with an average of at least 1 but no more than 8 migraines per month in the previous 6 months Enrolled (N = 104); did not receive study medication (N = 10); primary efficacy analysis (N = 94)
Interventions	Sumatriptan + naproxen sodium 85 mg + 500 mg; or placebo for the treatment of 4 migraine attacks (3 active, 1 placebo)
Outcomes	Pain freedom at 2 h (post‐treatment pain severity of 0 with no use of rescue medication) Presense of nausea or vomiting Use of rescue medications (within 24 h) Headache recurrence from 2‐24 h Adverse event Other reported outcomes: Presence of photophobia or phonophobia
Notes	—